Jamie P. Dwyer
( out of 43 reviews )

Jamie P. Dwyer, MD

Languages spoken: English

Clinical Locations

Primary Location

Kidney & Liver Clinic

Kidney and Liver Clinic
50 N Medical Dr
Salt Lake City , UT 84132
801-581-2772
Get Directions

  • Jamie P. Dwyer, MD, is the Assistant Vice-President for Clinical Research at the University of Utah Health in Salt Lake City, UT, USA. He is a Professor of Medicine in the Division of Nephrology & Hypertension, and Director of the Utah Data Coordinating Center and the Clinical Research Support Office. He is the current Principal Investigator of the Collaborative Study Group (CSG), an international academic research organization dedicated to the exceptionally rigorous design, conduct, analysis, and reporting of large, multi-center clinical trials. He has served on multiple Executive and Steering committees for large trials, particularly in CKD progression and cardiovascular outcomes. In 2015, Dr. Dwyer was appointed as a Consultant to the USA’s Food and Drug Administration’s (FDA) CardioRenal Advisory Committee, and has both served on and defended data before FDA Advisory Committees. In 2017, he and colleagues founded Innovative Renal Care, a health services delivery company dedicated to improving the care of dialysis patients in the United States. In 2023, he and colleagues founded Corventum, Inc.

    Dr. Dwyer is a practicing clinical nephrologist who sees patients across the spectrum of kidney disease. He is an accomplished and highly lauded educator, receiving numerous teaching awards, culminating in his election to Vanderbilt’s Academy for Excellence in Education while faculty there in 2013.

    Dr. Dwyer holds an ScB degree in Mathematics and Latin from Brown University in 1996, and an MD with Distinction from Brown University Medical School in 2000. He trained in Internal Medicine at Mayo Clinic Florida, where he served as Chief Medical Resident. He trained in Nephrology and Clinical Research at Vanderbilt University. After a faculty appointment at Mayo Clinic, he joined the Nephrology Division of Vanderbilt in 2008. In 2022, he joined the University of Utah. Dr. Dwyer is an attending physician and supervises fellows and residents in clinic and inpatient Nephrology services.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Nephrology)

    Patient Rating

    4.9 /5
    ( out of 43 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    UH HOSPITALS AND CLINICS

    Dr. Dwyer explains things in a way I understand and answers all of my questions

    UH HOSPITALS AND CLINICS

    Dr. Dwyer was professional,knowledgeable, caring and listened to my concerns.

    UH HOSPITALS AND CLINICS

    He is one of the best doctors I've ever seen & believe me I've seen a few. He is a huge asset too your facility!!

    UH HOSPITALS AND CLINICS

    Excitement specified skills and assignment follow through

    UH HOSPITALS AND CLINICS

    I was super impressed with Dr Dwyer. He was an active listener and carefully reviewed my unique health history. I am pleased with his approach and expertise. Very warm and caring.

    UH HOSPITALS AND CLINICS

    Very friendly, really knows what he is doing. Really appreciate him. He is such a good Dr

    UH HOSPITALS AND CLINICS

    Great doctor. Would recommend him to others.

    UH HOSPITALS AND CLINICS

    Listened to me exceptionally, and took my concerns into consideration in changing my meds.

    UH HOSPITALS AND CLINICS

    very personable, courteous, and professional

  • Jamie P. Dwyer, MD, is the Assistant Vice-President for Clinical Research at the University of Utah Health in Salt Lake City, UT, USA. He is a Professor of Medicine in the Division of Nephrology & Hypertension, and Director of the Utah Data Coordinating Center and the Clinical Research Support Office. He is the current Principal Investigator of the Collaborative Study Group (CSG), an international academic research organization dedicated to the exceptionally rigorous design, conduct, analysis, and reporting of large, multi-center clinical trials. He has served on multiple Executive and Steering committees for large trials, particularly in CKD progression and cardiovascular outcomes. In 2015, Dr. Dwyer was appointed as a Consultant to the USA’s Food and Drug Administration’s (FDA) CardioRenal Advisory Committee, and has both served on and defended data before FDA Advisory Committees. In 2017, he and colleagues founded Innovative Renal Care, a health services delivery company dedicated to improving the care of dialysis patients in the United States. In 2023, he and colleagues founded Corventum, Inc.

    Dr. Dwyer is a practicing clinical nephrologist who sees patients across the spectrum of kidney disease. He is an accomplished and highly lauded educator, receiving numerous teaching awards, culminating in his election to Vanderbilt’s Academy for Excellence in Education while faculty there in 2013.

    Dr. Dwyer holds an ScB degree in Mathematics and Latin from Brown University in 1996, and an MD with Distinction from Brown University Medical School in 2000. He trained in Internal Medicine at Mayo Clinic Florida, where he served as Chief Medical Resident. He trained in Nephrology and Clinical Research at Vanderbilt University. After a faculty appointment at Mayo Clinic, he joined the Nephrology Division of Vanderbilt in 2008. In 2022, he joined the University of Utah. Dr. Dwyer is an attending physician and supervises fellows and residents in clinic and inpatient Nephrology services.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Academic Divisions Nephrology & Hypertension
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Nephrology)

    Education history

    Undergraduate Mathematics - Brown University Sc.B.
    Undergraduate Classics: Latin - Brown University A.B.
    Professional Medical Medicine - Brown University School of Medicine M.D. with Distinction
    Residency Internal Medicine - Mayo Clinic Resident
    Residency Internal Medicine - Mayo Clinic Chief Resident
    Fellowship Nephrology/Hypertension - Vanderbilt University Clinical Fellow
    Research Fellow Nephrology/Hypertension - Vanderbilt University Research Fellow

    Selected Publications

    Journal Article

    1. Bridges MD, St Amant BS, McNeil RB, Cernigliaro JG, Dwyer JP, Fitzpatrick PM (2009). High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. AJR Am J Roentgenol, 192(6), 1538-43. (Read full publication)
    2. Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, Umanath K, Rahbari-Oskoui F, Porter AC, Pisoni R, Lewis CE, Lewis JB, Lash JP, Katz LA, Hawfield AT, Haley WE, Freedman BI, Dwyer JP, Drawz PE, Dobre M, Cheung AK, Campbell RC, Bhatt U, Beddhu S, Kimmel PL, Reboussin DM, Chertow GM, SPRINT Research Group (2018). Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis, 71(3), 352-361. (Read full publication)
    3. Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group (2015). The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Am J Kidney Dis, 66(3), 479-88. (Read full publication)
    4. McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D (2014). Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis, 64(5), 714-22. (Read full publication)
    5. Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D (2014). Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis, 63(2), 244-50. (Read full publication)
    6. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study Group (2013). Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis, 61(5), 759-66. (Read full publication)
    7. Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ (2012). Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis, 59(1), 75-83. (Read full publication)
    8. Elliott MR, Cortese C, Moreno-Aspitia A, Dwyer JP (2010). Plasma cell dyscrasia causing light chain tubulopathy without Fanconi syndrome. Am J Kidney Dis, 55(6), 1136-41. (Read full publication)
    9. Dwyer JP, Lewis JB (2011). Olmesartan to prevent the development of microalbuminuria: is it new? Is it true? Is it important? Am J Kidney Dis, 58(5), 700-3. (Read full publication)
    10. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I, Collaborative Study Group (2011). Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis, 58(5), 729-36. (Read full publication)
    11. Haglund NA, Feurer ID, Dwyer JP, Stulak JM, DiSalvo TG, Keebler ME, Schlendorf KH, Wigger MA, Maltais S (2014). Does renal dysfunction and method of bridging support influence heart transplant graft survival? Ann Thorac Surg, 98(3), 835-41. (Read full publication)
    12. Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP, Collaborative Study Group (2015). Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. J Am Soc Nephrol, 26(10), 2578-87. (Read full publication)
    13. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP, Collaborative Study Group (2015). Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol, 26(2), 493-503. (Read full publication)
    14. Hartle PM, Carlo ME, Dwyer JP, Fogo AB (2013). AKI in an HIV patient. J Am Soc Nephrol, 24(8), 1204-8. (Read full publication)
    15. Basford AW, Lewis J, Dwyer JP, Fogo AB (2011). Membranous nephropathy with crescents. J Am Soc Nephrol, 22(10), 1804-8. (Read full publication)
    16. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB, Collaborative Study Group (2012). Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol, 23(1), 131-6. (Read full publication)
    17. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC, Collaborative Study Group (2012). Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol, 23(1), 123-30. (Read full publication)
    18. Elliott MR, Soto Soto JM, Haley WE, Fitzpatrick PM, Dwyer JP (2013). Labile hypertension: characteristics of a referred cohort. Clin Exp Hypertens, 35(3), 207-12. (Read full publication)
    19. Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD, CAMELLIA-TIMI 61 Steering Committee and Investigator (2019). Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 139(3), 366-375. (Read full publication)
    20. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott S (2019). Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 139(22), 2528-2536. (Read full publication)
    21. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott S (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 139(22), 2516-2527. (Read full publication)
    22. Umanath K, Greco B, Jalal DI, McFadden M, Sika M, Koury MJ, Niecestro R, Hunsicker LG, Greene T, Lewis JB, Dwyer J (2017). The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis¿. Clinical nephrology, 87 (2017)(3), 124-133. (Read full publication)
    23. Dwyer JP, Yates KM, Sumner EL, Stone WJ, Wang Y, Koury MJ, Fogo AB, Zent (2007). Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy. Clinical nephrology, 67(3), 176-81. (Read full publication)
    24. Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz (2021). The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes care, 44(8), 1805-1815. (Read full publication)
    25. Shapiro BP, Ambrosius WT, Blackshear JL, Cushman WC, Whelton PK, Oparil S, Beddhu S, Dwyer JP, Gren LH, Kostis WJ, Lioudis M, Pisoni R, Rosendorff C, Haley WE, SPRINT Research Group (2018). Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension (Dallas, Tex., 71(6), 1064-1074. (Read full publication)
    26. Drawz PE, Pajewski NM, Bates JT, Bello NA, Cushman WC, Dwyer JP, Fine LJ, Goff DC Jr, Haley WE, Krousel-Wood M, McWilliams A, Rifkin DE, Slinin Y, Taylor A, Townsend R, Wall B, Wright JT, Rahman (2017). Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. Hypertension (Dallas, Tex., 69(1), 42-50. (Read full publication)
    27. Chang TI, Evans G, Cheung AK, Cushman WC, Diamond MJ, Dwyer JP, Huan Y, Kitzman D, Kostis JB, Oparil S, Rastogi A, Roumie CL, Sahay R, Stafford RS, Taylor AA, Wright JT Jr, Chertow GM, SPRINT Study Research Grou (2016). Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. Hypertension (Dallas, Tex., 67(3), 550-5. (Read full publication)
    28. Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, Banach (2018). Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney international, 93(6), 1397-1408. (Read full publication)
    29. Umana IE, Dwyer J (2009). Vicarious contrast excretion by the gallbladder in contrast nephropathy. Kidney international, 75(4), 446. (Read full publication)
    30. Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD, CAMELLIA-TIMI 61 Steering Committee Investigator (2018). Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet (London, England), 392(10161), 2269-2279. (Read full publication)
    31. Lette F, Dwyer J (2008). The fluid craze. Lancet (London, England), 372(9641), 782-4. (Read full publication)
    32. The Blood Pressure Lowering Treatment Trialists¿ Collaboratio Blood pressure lowering and risk of new-onset type 2 diabetes: an individual-level meta-analysis of 145,000 randomized participants. Lancet (London, England),
    33. The Blood Pressure Lowering Treatment Trialists¿ Collaboratio (2021). Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet (London, England), 398(10305), 1053-1064.
    34. Dwyer JP, Lewis J (2013). Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook. The Medical clinics of North America, 97(1), 53-8. (Read full publication)
    35. Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Górriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjöström CD, Langkilde AM, Heerspink HJ (2020). The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology, dialysis, transplantation, 35(10), 1700-1711. (Read full publication)
    36. Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC, DAPA-CKD Investigator (2020). Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology, dialysis, transplantation, 35(2), 274-282. (Read full publication)
    37. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG, SCORED Investigator (2021). Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. The New England journal of medicine, 384(2), 129-139. (Read full publication)
    38. Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, Connolly LE, Miller LG, Friedland I, Dwyer JP, EPIC Study Grou (2019). Once-Daily Plazomicin for Complicated Urinary Tract Infections. The New England journal of medicine, 380(8), 729-740. (Read full publication)
    39. SPRINT Research Group., Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius W (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine, 384(20), 1921-1930. (Read full publication)
    40. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigator (2020). Dapagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine, 383(15), 1436-1446. (Read full publication)
    41. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE'TIMI 58 Investigator (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 380(4), 347-357. (Read full publication)
    42. Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA-TIMI 61 Steering Committee and Investigator (2018). Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. The New England journal of medicine, 379(12), 1107-1117. (Read full publication)
    43. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J, SPRINT Research Grou (2017). Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. The New England journal of medicine, 377(8), 733-744. (Read full publication)
    44. SPRINT Research Group., Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius W (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine, 373(22), 2103-16. (Read full publication)
    45. Dwyer JP, Greco BA, Umanath K, Packham D, Fox JW, Peterson R, Broome BR, Greene LE, Sika M, Lewis J (2015). Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study. Nephron, 129(1), 22-8. (Read full publication)
    46. Tamura MK, Pajewski NM, Bryan RN, Weiner DE, Diamond M, Van Buren P, Taylor A, Beddhu S, Rosendorff C, Jahanian H, Zaharchuk G, SPRINT Study Research Grou (2016). Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. Neurology, 86(13), 1208-16. (Read full publication)
    47. Nogid B, Lacy MK, Jacobs M, Bruss J, Dwyer (2018). Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials. Pharmacotherapy, 38(10), 990-998. (Read full publication)
    48. Cox ZL, Sarrell BA, Cella MK, Tucker B, Arroyo JP, Umanath K, Tidwell W, Guide A, Testani JM, Lewis JB, Dwyer J (2021). Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience. Journal of cardiac failure, (Read full publication)
    49. Rodby RA, Umanath K, Niecestro R, Bond TC, Sika M, Lewis J, Dwyer JP, Collaborative Study Grou (2015). Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data. Drugs in R&D, 15(3), 271-9. (Read full publication)
    50. Dwyer J (2016). We Give Too Much Intravenous Iron. Seminars in dialysis, 29(4), 309-11. (Read full publication)
    51. Umanath K, Morrison RS, Christopher Wilbeck J, Schulman G, Bream P, Dwyer J (2013). In-center thrombolysis for clotted AV access: a cohort review. Seminars in dialysis, 26(1), 124-9. (Read full publication)
    52. Dwyer JP, Greco BA, Lewis J (2009). Evaluation of renal artery stenosis in dialysis patients. Seminars in dialysis, 22(5), 519-23. (Read full publication)
    53. Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez J (2009). Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. The AIDS reader, 19(3), 114-21. (Read full publication)
    54. van der Sande NG, Dorresteijn JA, Visseren FL, Dwyer JP, Blankestijn PJ, van der Graaf Y, Heerspink H (2016). Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy. Diabetes, obesity & metabolism, 18(11), 1120-1127. (Read full publication)
    55. Schievink B, Kröpelin T, Mulder S, Parving HH, Remuzzi G, Dwyer J, Vemer P, de Zeeuw D, Lambers Heerspink H (2016). Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes, obesity & metabolism, 18(1), 64-71. (Read full publication)
    56. Packham DK, Ivory SE, Reutens AT, Wolfe R, Rohde R, Lambers Heerspink H, Dwyer JP, Atkins RC, Lewis J, Collaborative Study Grou (2011). Proteinuria in type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathy. Nephron. Clinical practice, 118(4), c331-8. (Read full publication)
    57. Sinsakul M, Sika M, Koury M, Shapiro W, Greene T, Dwyer J, Smith M, Korbet S, Lewis J, Collaborative Study Grou (2012). The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron. Clinical practice, 121(1-2), c25-9. (Read full publication)
    58. Umanath K, Lewis JB, Dwyer J (2014). Optimizing blood pressure control in patients with nondiabetic glomerular disease. Advances in chronic kidney disease, 21(2), 200-4. (Read full publication)
    59. Waguespack DR, Dwyer J (2019). Assessment of Blood Pressure: Techniques and Implications From Clinical Trials. Advances in chronic kidney disease, 26(2), 87-91. (Read full publication)
    60. Jalal D, McFadden M, Dwyer JP, Umanath K, Aguilar E, Yagil Y, Greco B, Sika M, Lewis JB, Greene T, Goral (2017). Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis. Hemodialysis international. International Symposium on Home Hemodialysis, 21(2), 243-249. (Read full publication)
    61. Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP, Collaborative Study Grou (2013). Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodialysis international. International Symposium on Home Hemodialysis, 17(1), 67-74. (Read full publication)
    62. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK, SPRINT Study Research Grou (2014). The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clinical trials (London, England), 11(5), 532-46. (Read full publication)
    63. Supiano MA, Lovato L, Ambrosius WT, Bates J, Beddhu S, Drawz P, Dwyer JP, Hamburg NM, Kitzman D, Lash J, Lustigova E, Miracle CM, Oparil S, Raj DS, Weiner DE, Taylor A, Vita JA, Yunis R, Chertow GM, Chonchol (2018). Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. PloS one, 13(9), e0203305. (Read full publication)
    64. Burgner A, Ikizler TA, Dwyer J (2020). COVID-19 and the Inpatient Dialysis Unit: Managing Resources during Contingency Planning Pre-Crisis. Clinical journal of the American Society of Nephrology, 15(5), 720-722. (Read full publication)
    65. Weldegiorgis M, de Zeeuw D, Dwyer JP, Mol P, Heerspink HJ (2017). Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?. Clinical journal of the American Society of Nephrology, 12(10), 1595-1600. (Read full publication)
    66. Siew ED, Ikizler TA, Matheny ME, Shi Y, Schildcrout JS, Danciu I, Dwyer JP, Srichai M, Hung AM, Smith JP, Peterson J (2012). Estimating baseline kidney function in hospitalized patients with impaired kidney function. Clinical journal of the American Society of Nephrology, 7(5), 712-9. (Read full publication)
    67. Rodby R, Umanath K, Niecestro R, Jackson JH, Sika M, Lewis JB, Dwyer JP, Collaborative Study Grou (2015). Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert review of pharmacoeconomics & outcomes research, 15(3), 545-50. (Read full publication)
    68. Umanath K, Niecestro R, Lewis JB, Dwyer J (2013). Ferric citrate: a novel phosphate-binding agent. Expert review of endocrinology & metabolism, 8(1), 13-19. (Read full publication)
    69. Sinsakul M, Rodby R, Umanath K, Niecestro R, Dwyer J (2014). Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data. Expert review of clinical pharmacology, 7(6), 705-10. (Read full publication)
    70. Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis J (2012). Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. Cardiorenal medicine, 2(1), 1-10. (Read full publication)
    71. Coffin ST, Waguespack DR, Haglund NA, Maltais S, Dwyer JP, Keebler M (2015). Kidney dysfunction and left ventricular assist device support: a comprehensive perioperative review. Cardiorenal medicine, 5(1), 48-60. (Read full publication)
    72. Rahimi K, Canoy D, Nazarzadeh M, Salimi-Khorshidi G, Woodward M, Teo K, Davis BR, Chalmers J, Pepine CJ, The Blood Pressure Lowering Treatment Trialists¿ Collaboratio (2019). Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). BMJ open, 9(5), e028698. (Read full publication)
    73. Fatima H, Siew ED, Dwyer JP, Paueksakon (2012). Membranous glomerulopathy with superimposed pauci-immune necrotizing crescentic glomerulonephritis. Clinical kidney journal, 5(6), 587-90. (Read full publication)
    74. Drawz PE, Agarwal A, Dwyer JP, Horwitz E, Lash J, Lenoir K, McWilliams A, Oparil S, Rahbari-Oskoui F, Rahman M, Parkulo MA, Pemu P, Raj DS, Rocco M, Soman S, Thomas G, Tuot DS, Whelton PK, Pajewski N (2020). Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice. JAMA internal medicine, 180(12), 1655-1663. (Read full publication)
    75. Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz (2019). Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. The lancet. Diabetes & endocrinology, 7(8), 606-617. (Read full publication)
    76. Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA, Chronic Kidney Disease Epidemiology Collaboratio (2019). Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. The lancet. Diabetes & endocrinology, 7(2), 128-139. (Read full publication)
    77. Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott S (2021). Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA cardiology, 6(7), 801-810. (Read full publication)
    78. Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J, Focal Segmental Glomerulosclerosis Study Grou (2017). A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis. Kidney international reports, 2(5), 800-810. (Read full publication)
    79. Nissen SE, Wang Q, Nicholls SJ, Zerlasiran, et. a (2024). A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA,
    80. Brulotte M, Alvey JS, Casper TC, Cook LJ, Dwyer JP, VanBuren J (2024). A risk- based approached to source data monitoring and documenting monitoring findings. Contemporary clinical trials communications,
    81. Nissen SE, Wolski K, Watts GF, et a (2024). Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. JAMA, 18(331), 1534¿1543.
    82. Rowan CG, Agiro A, Chan KA, Colman E, White K, Desai P, Dwyer J Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3–4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study. Advanced therapeutics,
    83. The Blood Pressure Lowering Treatment Trialists¿ Collaboratio (2021). Age and blood pressure stratified effects of blood pressure- lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual-level meta-analysis of 358,707 randomised participants. Lancet (Edizione Italiana), The, 10305(398), 1053-1064.
    84. Lane K, Palm M, Marion E, Kay M, Thompson D, Stroud M, Boyle H, Hillery S, Nanni A, Hildreth M, Nelson S, Burr JS, Edwards T, Poole L, Waddy SP, Dunsmore SE, Harris P, Wilkins C, Bernard GB, Dean JM, Dwyer JP, Benjamin Jr, DK, Selker HP, Hanley DF, Ford (2023). Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation Network. Journal of clinical and translational science, 7(1), E131.
    85. Moura FA, Berg DD, Bellavia A, Dwyer JP, Mosenzon O, Scirica BM, Wiviott SD, Bhatt DL, Raz I, Feinberg MW, Braunwald E, Morrow DA, Sabatine M (2023). Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes care, 46(10), 1-9.
    86. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH, SELECT Trial Investigator (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Epub, 389(24), 2221-2232.
    87. Cooper M, Cherney DZI, Greene TH, Heerspink HJL, Jardine M, Lewis JB, Wong MG, Baquero E, Heise M, Jochems J, Lanchoney D, Liss C, Reiser D, Scotney P, Velkoska E, Dwyer J (2024). Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial. Journal of the American Society of Nephrology, 35(11), 1546-1557. (Read full publication)
    88. Brulotte M, Alvey JS, Casper TC, Cook LJ, Dwyer JP, VanBuren J (2024). A risk-based monitoring approach to source data monitoring and documenting monitoring findings. Contemporary clinical trials, 143, 107581. (Read full publication)
    89. Chertow GM, Heerspink HL, Mark PB, Dwyer JP, Nowicki M, Wheeler DC, Correa-Rotter R, Rossing P, Toto RD, Langkilde AM, Jongs (2024). Effects of Dapagliflozin in Patients with Membranous Nephropathy. Glomerular diseases, 4(1), 137-145. (Read full publication)
    90. Rowan CG, Agiro A, Chan KA, Colman E, White K, Desai P, Dwyer J (2024). Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3-4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study. Advances in therapy, 41(6), 2381-2398. (Read full publication)
    91. Heerspink HJL, Greasley PJ, Ahlström C, Althage M, Dwyer JP, Law G, Wijkmark E, Lin M, Mercier AK, Sunnåker M, Turton M, Wheeler DC, Ambery (2024). Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial. Nephrology, dialysis, transplantation, 39(3), 414-425. (Read full publication)
    92. Drawz PE, Lenoir KM, Rai NK, Rastogi A, Chu CD, Rahbari-Oskoui FF, Whelton PK, Thomas G, McWilliams A, Agarwal AK, Suarez MM, Dobre M, Powell J, Rocco MV, Lash JP, Oparil S, Raj DS, Dwyer JP, Rahman M, Soman S, Townsend RR, Pemu P, Horwitz E, Ix JH, Tuot DS, Ishani A, Pajewski N (2024). Effect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINT. Clinical journal of the American Society of Nephrology, 19(2), 213-223. (Read full publication)
    93. Cummins MR, Burr J, Young L, Yeatts SD, Ecklund DJ, Bunnell BE, Dwyer JP, VanBuren J (2023). Decentralized research technology use in multicenter clinical research studies based at U.S. academic research centers. Journal of clinical and translational science, 7(1), e250. (Read full publication)
    94. Palm ME, Thompson DD, Edwards T, Swartz K, Herzog KA, Bansal S, Echalier B, DeHart KC, Denmark S, Wilson JL, Nelson S, Waddy SP, Dunsmore SE, Atkinson JC, Wiley K Jr, Hassani S, Dwyer JP, Hanley DF, Dean JM, Ford D (2023). The Trial Innovation Network Liaison Team: building a national clinical and translational community of practice. Journal of clinical and translational science, 7(1), e249. (Read full publication)
    95. Dwyer JP, Agiro A, Desai P, Oluwatosin (2023). Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study. Advances in therapy, 40(11), 4777-4791. (Read full publication)
    96. Palm ME, Edwards TL, Wieber C, Kay MT, Marion E, Boone L, Nanni A, Jones M, Pham E, Hildreth M, Lane K, McBee N, Benjamin DK Jr, Bernard GR, Dean JM, Dwyer JP, Ford DE, Hanley DF, Harris PA, Wilkins CH, Selker H (2023). Development, implementation, and dissemination of operational innovations across the trial innovation network. Journal of clinical and translational science, 7(1), e251. (Read full publication)
    97. Harris PA, Dunsmore SE, Atkinson JC, Benjamin DK Jr, Bernard GR, Dean JM, Dwyer JP, Ford DF, Selker HP, Waddy SP, Wiley KL, Wilkins CH, Cook SK, Burr JS, Edwards TL, Huvane J, Kennedy N, Lane K, Majkowski R, Nelson S, Palm ME, Stroud M, Thompson DD, Busacca L, Elkind MSV, Kimberly RP, Reilly MP, Hanley DF, Trial Innovation Networ (2023). Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical Trials. JAMA network open, 6(10), e2336470. (Read full publication)
    98. Moura FA, Berg DD, Bellavia A, Dwyer JP, Mosenzon O, Scirica BM, Wiviott SD, Bhatt DL, Raz I, Feinberg MW, Braunwald E, Morrow DA, Sabatine M (2023). Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes care, 46(10), 1807-1815. (Read full publication)
    99. Agiro A, Dwyer JP, Oluwatosin Y, Desai (2023). Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study. ClinicoEconomics and outcomes research, 15, 691-702. (Read full publication)
    100. Dwyer JP, Agiro A, Desai P, Cremisi (2023). Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study. Expert review of pharmacoeconomics & outcomes research, 23(9), 1057-1066. (Read full publication)
    101. Chu CD, Lenoir KM, Rai NK, Soman S, Dwyer JP, Rocco MV, Agarwal AK, Beddhu S, Powell JR, Suarez MM, Lash JP, McWilliams A, Whelton PK, Drawz PE, Pajewski NM, Ishani A, Tuot D (2023). Concordance between clinical outcomes in the Systolic Blood Pressure Intervention Trial and in the electronic health record. Contemporary clinical trials, 128, 107172. (Read full publication)
    102. Mosenzon O, Raz I, Wiviott SD, Schechter M, Goodrich EL, Yanuv I, Rozenberg A, Murphy SA, Zelniker TA, Langkilde AM, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Wilding JPH, McGuire DK, Bhatt DL, Leiter LA, Cahn A, Dwyer JP, Heerspink HJL, Sabatine M (2022). Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Diabetes care, 45(10), 2350-2359. (Read full publication)
    103. Drawz PE, Rai NK, Lenoir KM, Suarez M, Powell JR, Raj DS, Beddhu S, Agarwal AK, Soman S, Whelton PK, Lash J, Rahbari-Oskoui FF, Dobre M, Parkulo MA, Rocco MV, McWilliams A, Dwyer JP, Thomas G, Rahman M, Oparil S, Horwitz E, Pajewski NM, Ishani (2022). Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study. Kidney360, 3(7), 1253-1262. (Read full publication)
    104. Canoy D, Copland E, Nazarzadeh M, Ramakrishnan R, Pinho-Gomes AC, Salam A, Dwyer JP, Farzadfar F, Sundström J, Woodward M, Davis BR, Rahimi K, Blood Pressure Lowering Treatment Trialists' Collaboration, Blood Pressure Lowering Treatment Trialists Collaboratio (2022). Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials. Heart (British Cardiac Society), 108(16), 1281-1289. (Read full publication)
    105. Zuo Y, Cavalcante LB, Smelser JM, Sanghani N, Dwyer JP, Lewis JB, Fogo A (2021). Anti-Phospholipase A2 Receptor in Nonlupus Patients with Membranous Nephropathy and Crescents. Glomerular diseases, 2(2), 75-82. (Read full publication)
    106. Heerspink HJL, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, Wheeler DC, DAPA-CKD Trial Committees and Investigator (2022). A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney international, 101(1), 174-184. (Read full publication)
    107. Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene (2019). Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. Journal of the American Society of Nephrology, 30(8), 1523-1533. (Read full publication)

    Review

    1. Dwyer JP, Kelepouris (2023). New Directions in Phosphorus Management in Dialysis. Journal of renal nutrition, 33(1), 12-16. (Read full publication)
    2. Heyman SN, Raz I, Dwyer JP, Weinberg Sibony R, Lewis JB, Abassi (2022). Diabetic Proteinuria Revisited: Updated Physiologic Perspectives. Cells, 11(18), (Read full publication)

    Book Chapter

    1. Huston HK, Dwyer J (2018). Advances in the Management of Hyperkalemia.

    Conference Proceedings

    1. Eckardt KU, Bansal N, Coresh J, Evans M, Grams ME, Herzog CA, James MT, Heerspink HJL, Pollock CA, Stevens PE, Tamura MK, Tonelli MA, Wheeler DC, Winkelmayer WC, Cheung M, Hemmelgarn BR, Conference Participant (2018). Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international, 93(6), 1281-1292. (Read full publication)

    Editorial

    1. Umanath K, Burgner A, Lewis JB, Dwyer JP (2014). Guidelines and Straitjackets: blood pressure targets in the era of the Eighth Joint National Committee. Am J Kidney Dis, 63(6), 895-9. (Read full publication)

    Letter

    1. McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, Jubb AM, Serio AW, Krause KM, Daikos GL, CARE Study Grou (2019). Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. The New England journal of medicine, 380(8), 791-793. (Read full publication)
    2. Dwyer JP, Cohen M (2005). Interns' work hours. The New England journal of medicine, 352(7), 726-8; author reply 726-8. (Read full publication)
    3. Choma DP, Cavanaugh KL, Dwyer J (2010). Is it always wrong to perform futile CPR?. The New England journal of medicine, 362(21), 2036; author reply 2036-7. (Read full publication)